стоимость квадратного метра по регионам на 2017 год
Главное меню:
Интересное
стоимость квадратного метра по регионам на 2017 год, Treatment of Hyperlipidemia in HIV-Infected Patients - Medscape, Exercising With Hyperlipidemia: Prescription for Health - Medscape, Hyperlipidemia Management Depends on the Details - Medscape, Hyperlipidemia in Racial/Ethnic Minorities - Medscape, FDA Updates Labels for Two Cholesterol-Lowering Agents - Medscape, ECG Challenge: Hyperlipidemia and Irregular Pulse - Medscape, Gene Silencing Benefit of Zodasiran in Hyperlipidemia - Medscape.
Hyperlipidemia is common in HIV-infected patients receiving antiretroviral therapy, especially protease inhibitors and stavudine. The recommendations of the National Cholesterol Education Program (NCEP) may not entirely apply to HIV-infected patients. The pathogenesis of hyperlipidemia in these patients may make them refractory to traditional pharmacotherapy, and NCEP's emphasis on diet and exercise may be unrealistic. Other factors that may complicate treatment of hyperlipidemia include metabolism of many antiretroviral drugs by the cytochrome P-450 isoenzyme system, polypharmacy, and drug-food interactions. A patient's cardiac risk should first be assessed. Nonpharmacologic measures, such as a low-fat diet, weight reduction, and exercise, should be considered. Drug therapy is indicated for patients with familial combined hyperlipidemia that is associated with atherogenesis and for patients with triglyceride concentrations exceeding 1000 mg/dL. Drug therapy for hyperlipidemia involves niacin and statins, in addition to fibric acid derivatives and probucol. Switching among antiretroviral agents when one is found to cause hyperlipidemia should be done cautiously because of the risk for viral rebound and disease progression. NCEP guidelines recommend monitoring low-density-lipoprotein cholesterol levels four to six weeks after the start of lipid-lowering therapy and then at three months; more frequent monitoring may be necessary in HIV-infected patients., Hyperlipidemia is common in HIV-infected patients receiving antiretroviral therapy, especially protease inhibitors and stavudine. The recommendations of the National Cholesterol Education Program , Hyperlipidemia, which is having blood cholesterol and/or triglyceride levels that are too high, is a risk factor for many forms of cardiovascular disease. Regular physical activity, when combined .
Combined hyperlipidemia is defined as increased low-density lipoprotein (LDL) cholesterol, decreased high-density lipoprotein (HDL) cholesterol, and increased triglyceride levels., Hyperlipidemia is a powerful and extremely common risk factor for cardiovascular disease (CVD), and it is clear that cholesterol-lowering therapy, with LDL-C as a primary target, is beneficial in , Bempedoic acid and bempedoic acid/ezetimibe are indicated as adjuncts to diet and statin therapy for the treatment of primary hyperlipidemia in adults with heterozygous familial , A 48-year-old man presents to his primary care provider for a routine physical examination. He has a history of hyperlipidemia; he does not have any known heart disease. His pulse is noted to be , The phase 2b ARCHES-2 trial involved patients with mixed hyperlipidemia who had fasting triglyceride levels of 150-499 mg/dL and either an LDL cholesterol level ≥ 70 mg/dL or a non–high , The first step in management of a person with hyperlipidemia is CHD risk assessment comprising mainly of two aspects, lipoprotein analysis and other risk factor identification by clinical and .